Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-09
Target enrollment:
Participant gender:
Summary
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \<360 mol/L at 24 weeks; secondary endpoints included the proportion of weight loss 5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1; the activity of AMPK in PBMCs and the expression of HIF1 and NLRP3 inflammasome-related proteins were also assessed.
Phase:
NA
Details
Lead Sponsor:
XueMei Guo
Collaborators:
Shengjing Hospital The People's Hospital of Liaoning Province